|

Arthritis Clinical Trials in Ohio

31 recruiting studies across 2 cities

Browse by City

Cleveland
24 trials
Columbus
12 trials

All Trials in Ohio

Phase
Trial Phase Dist.
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry—<1 mi
Preventing Injured Knees From osteoArthritis: Severity OutcomesPhase 2<1 mi
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)Phase 1<1 mi
The Myelin Disorders Biorepository Project—<1 mi
MOTION Clinical TrialN/A<1 mi
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic PainPhase 2<1 mi
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritisPhase 3<1 mi
IMPACT - AndHealth Autoimmune Research Registry—<1 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable CancerPhase 1<1 mi
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesPhase 3<1 mi
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry—<1 mi
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic MedicinesPhase 3<1 mi
Improving Total Knee Arthroplasty Dissatisfaction Through a Personalized Approach Focusing on PROMs PhenotypesN/A<1 mi
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)—<1 mi
RA-PRO PRAGMATIC TRIALPhase 3<1 mi
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic ArthritisPhase 3<1 mi
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabPhase 3<1 mi
Persona Revision Knee System Outcomes—<1 mi
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).Phase 1<1 mi
A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension—<1 mi
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesPhase 2<1 mi
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugPhase 311 mi
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisPhase 211 mi
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic ArthritisPhase 311 mi
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid ArthritisPhase 211 mi
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)Phase 411 mi
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic ArthritisPhase 211 mi
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponsePhase 311 mi
Evaluate the Safety and Effectiveness of the Polymotion Hip Resurfacing (PHR) System Compared to Total Hip ArthroplastyN/A13 mi
Safety and Effectiveness of the HIT Reverse HRSN/A13 mi
Exactech Shoulder Post Market Clinical Follow-up Study—30 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.